von Willebrand Disease

Von Willebrand disease (VWD) is the most common hereditary bleeding disorder, characterized by quantitative or qualitative deficiency of von Willebrand factor (vWF), a multimeric glycoprotein essential for primary hemostasis and factor VIII carrier protein. The disorder affects approximately 1% of the general population (0.6–1.3% prevalence), though clinically significant disease occurs in 0.1%, with equal gender distribution despite X-linked inheritance patterns in some families. VWD presents with mucocutaneous bleeding manifestations including epistaxis, gingival bleeding, excessive menstrual bleeding, and post-traumatic hemorrhage, making it a critical differential diagnosis in any patient with bleeding symptoms or abnormal coagulation studies. Understanding VWD is essential for board examination preparation because it represents the intersection of primary and secondary hemostasis, frequently appears in clinical vignettes involving women with menorrhagia, and requires nuanced interpretation of laboratory studies that may vary with stress, exercise, estrogen, and other factors. The disease has three major types with distinct pathophysiology and management implications, and misdiagnosis commonly occurs due to overlap with factor VIII deficiency or platelet dysfunction disorders.

Von Willebrand factor is a large, multimeric glycoprotein synthesized in endothelial cells and megakaryocytes that serves dual critical functions in hemostasis. The vWF gene (chromosome 12, 178 kb) contains 52 exons and undergoes complex post-translational processing, including proteolytic cleavage by the metalloprotease ADAMTS13 to generate appropriately sized multimers. The protein exists as ultra-large vWF multimers (ULVWF) that are progressively cleaved into smaller, circulating multimers of varying sizes (ranging from dimers to multimers exceeding 20,000 kDa). vWF functions as both an adhesive molecule that mediates platelet adhesion to exposed subendothelial collagen via the glycoprotein Ib-IX-V complex and as a carrier protein that binds and stabilizes factor VIII, protecting it from proteolytic degradation in plasma. Approximately 75–80% of circulating factor VIII is bound to vWF, and loss of vWF results in parallel reductions in factor VIII levels due to accelerated clearance.

Type 1 VWD, accounting for 75–80% of clinical cases, results from proportional reductions in vWF antigen (vWF:Ag), vWF ristocetin cofactor activity (vWF:RCo), and factor VIII activity, typically with vWF:RCo/vWF:Ag ratios >0.6. The molecular basis involves heterozygous loss-of-function mutations affecting vWF synthesis, stability, or secretion, with inheritance demonstrating variable penetrance and expressivity. The defect does not involve impaired multimer assembly per se but rather reduced production or accelerated clearance of normally proportioned multimers. Patients typically have vWF and factor VIII levels of 20–80% of normal, and bleeding manifestations reflect both impaired platelet adhesion (primary hemostasis abnormality) and reduced factor VIII availability (secondary hemostasis defect). The dominant inheritance pattern results from haploinsufficiency, where a single mutant allele produces insufficient vWF to maintain normal hemostasis, though inheritance can occasionally be autosomal recessive in consanguineous populations or autosomal dominant with incomplete penetrance.

Type 2 VWD encompasses multiple subtypes (2A, 2B, 2M, 2N) characterized by disproportionate reduction of high-molecular-weight multimers relative to vWF:Ag, manifesting as a vWF:RCo/vWF:Ag ratio <0.6. Type 2A, the most common subtype (60% of Type 2), results from mutations affecting either vWF synthesis (Group I mutations with normal-to-reduced vWF:Ag) or ADAMTS13-mediated cleavage sites (Group II mutations with loss of high-molecular-weight multimers and reduced vWF:Ag). The pathophysiology involves preferential retention or loss of functionally superior high-molecular-weight multimers, which possess the greatest platelet-adhesive capacity because they provide multiple simultaneous binding sites for platelet glycoprotein Ib. Type 2B VWD results from gain-of-function mutations in the glycoprotein Ib-binding domain that cause spontaneous, enhanced binding of vWF to platelets, leading to in vivo platelet clearance and selective loss of high-molecular-weight multimers in the circulation; this mechanism paradoxically produces both thrombocytopenia and bleeding. Type 2M involves mutations affecting vWF interaction with platelets without altering multimer structure, while Type 2N involves mutations in the factor VIII-binding domain, producing a phenotype resembling mild hemophilia A with disproportionately low factor VIII relative to vWF:Ag.

Type 3 VWD results from homozygous or compound heterozygous null mutations in the vWF gene causing complete absence of circulating vWF and absent or nearly absent factor VIII (<10% normal), representing the most severe form of the disease. The pathophysiology involves loss of all vWF functions, eliminating both platelet adhesion capability and factor VIII stabilization. Patients inherit two copies of loss-of-function mutations (autosomal recessive inheritance) or occasionally compound heterozygous mutations involving different genetic defects. The severe deficiency produces not only mucocutaneous bleeding but also risk of spontaneous soft-tissue hematomas, hemarthroses, and gastrointestinal bleeding, resembling mild-to-moderate hemophilia A in clinical severity. Notably, Type 3 patients face significant risk of developing alloimmunization to vWF with development of inhibitor antibodies upon exposure to vWF-containing products because they may not tolerate the "foreign" vWF protein.

Von Willebrand factor levels are dynamic and influenced by multiple physiological and pathological factors that substantially affect laboratory diagnosis. Physical stress and catecholamine release trigger endothelial cell secretion of stored vWF, explaining why vWF levels rise with exercise, emotional stress, and epinephrine administration; this physiological variation complicates diagnosis because stress during phlebotomy can falsely normalize vWF levels in affected individuals. Estrogen increases vWF synthesis and levels substantially (explaining why women on oral contraceptives or hormone replacement therapy may have normalized vWF levels), and estrogen deficiency in postmenopausal women results in reduced vWF. ABO blood group strongly influences vWF levels, with type O individuals having 25–30% lower vWF levels than types A, B, or AB due to an ABO antigen-vWF glycosylation interaction affecting vWF clearance; this creates a population variation that may confound diagnosis in Type 1 patients with borderline levels. Acute phase response, thyroid hormone, and inflammation all increase vWF synthesis, while hypothyroidism and elevated ADAMTS13 activity reduce vWF levels. ADAMTS13 (a disintegrin and metalloproteinase with thrombospondin type 1 motif, member 13) is the specific vWF-cleaving protease that regulates circulating vWF multimer size distribution; its activity increases with stress and inflammation, promoting cleavage of ultra-large multimers into smaller, less adhesive forms. These dynamic factors create significant day-to-day and moment-to-moment variability in vWF measurements, often requiring multiple measurements over time to establish a diagnosis of Type 1 VWD reliably.

The bleeding diathesis in VWD stems from two complementary defects: (1) impaired primary hemostasis due to reduced platelet adhesion capacity when high-molecular-weight vWF multimers are absent or reduced, manifesting as prolonged bleeding time and mucocutaneous bleeding; and (2) secondary hemostasis impairment resulting from reduced factor VIII levels causing defective intrinsic tenase complex formation and thrombin generation. The relative contribution of each defect varies by VWD type: Type 1 disease produces parallel reductions in both platelet adhesion and factor VIII, while Type 2 disease causes disproportionate loss of platelet-adhesive function relative to vWF mass. In Type 2B disease, the bleeding paradoxically results from both loss of functional vWF (due to continued in vivo clearance) and thrombocytopenia (from platelet binding and clearance), creating a dual hemostatic defect. The bleeding phenotype characteristically manifests as mucocutaneous bleeding (epistaxis, gingival bleeding, menorrhagia) reflecting the primary hemostatic defect, though joint and soft-tissue bleeding can occur particularly in Type 3 disease when factor VIII is severely reduced.

Type 1 VWD results from heterozygous mutations in the vWF gene causing reduced synthesis, impaired secretion, or accelerated clearance of vWF. The inheritance pattern is autosomal dominant with incomplete penetrance and variable expressivity, meaning not all mutation carriers develop clinically significant disease and severity varies widely within families. The underlying mutations include missense mutations affecting the D1-D2 propeptide region (interfering with vWF multimerization), nonsense mutations causing haploinsufficiency, and deletions/insertions disrupting the reading frame. Approximately 75% of patients with clinical VWD have Type 1 disease, making it the most commonly encountered form. The disease requires only one mutant allele for manifestation due to haploinsufficiency, and affected individuals typically have vWF and factor VIII levels ranging from 20–80% of normal. The variable expressivity reflects both genetic modifiers and acquired factors (discussed above) that modulate vWF levels.

Type 2 VWD results from point mutations or small deletions/insertions affecting specific functional domains of vWF rather than simply reducing total protein quantity. Type 2A accounts for approximately 60% of Type 2 cases and results from Group I mutations affecting vWF synthesis/processing or Group II mutations affecting ADAMTS13 cleavage sites, leading to loss of high-molecular-weight multimers. Type 2B (approximately 25% of Type 2) arises from gain-of-function mutations in the glycoprotein Ib-binding domain, most commonly involving residues 473–909 that constitute the A1 domain; these mutations increase spontaneous vWF-platelet interaction without requiring shear stress, causing enhanced platelet binding and in vivo clearance. Type 2M (approximately 5% of Type 2) results from mutations impairing vWF-glycoprotein Ib interaction without altering multimer structure. Type 2N is the rarest subtype, resulting from mutations in the N-terminal factor VIII-binding region that produces a phenotype resembling mild factor VIII deficiency. Type 2 VWD characteristically demonstrates autosomal dominant inheritance with variable penetrance, though Type 2N typically shows autosomal recessive inheritance. Inheritance pattern determination requires careful genotyping and functional studies since Type 2B may appear autosomal dominant while Type 2N appears recessive.

Type 3 VWD results from homozygous null mutations, compound heterozygous mutations, or occasionally large deletions completely eliminating vWF expression. The genetic basis includes nonsense mutations producing premature termination codons, frameshift mutations, large gene deletions, and occasionally splice-site mutations. The inheritance pattern is strictly autosomal recessive, requiring two mutant copies for disease manifestation; parents are typically obligate carriers with Type 1 VWD. Type 3 represents only 5–10% of VWD cases but produces the most severe bleeding manifestations. Patients completely lack vWF protein and typically have undetectable or near-undetectable factor VIII levels (<10% normal), approaching the severity of mild hemophilia A. The complete absence of vWF creates risk of allo-immunization upon exposure to vWF-containing replacement therapy in some patients, as approximately 8–13% of Type 3 patients develop inhibitor antibodies (compared to virtually absent allo-immunization in Type 1 and Type 2 disease).

Acquired VWD represents secondary loss or dysfunction of vWF in patients without a family history of bleeding or congenital VWD mutations. The pathophysiology involves acquired vWF loss, increased vWF consumption, or impaired synthesis in the setting of underlying systemic disease. AVWD associated with lymphoproliferative disorders (lymphomas, chronic lymphocytic leukemia) results from monoclonal paraprotein-vWF immune complexes causing vWF clearance or from anti-vWF autoantibodies; this presents insidiously with new-onset bleeding in elderly or middle-aged patients. AVWD in cardiac disease (particularly aortic stenosis and ventricular assist devices) results from high shear stress causing ADAMTS13-mediated cleavage of ultra-large vWF multimers, producing a Type 2-like pattern with preferential loss of high-molecular-weight forms. AVWD in myeloproliferative neoplasms occurs through vWF consumption by platelet binding or concurrent factor VIII inhibitor development. AVWD with autoimmune disease (systemic lupus erythematosus, antiphospholipid syndrome) may result from anti-vWF antibodies or concurrent lupus anticoagulant affecting factor VIII. Drug-induced AVWD has been reported with valproic acid, ciprofloxacin, and indomethacin, though mechanisms remain incompletely understood. The diagnosis of AVWD requires absence of family history and exclusion of congenital VWD subtypes through genetic testing, as management differs substantially (targeting underlying disease rather than vWF replacement).

Epistaxis represents the most common bleeding symptom in VWD, occurring in 40–80% of affected individuals, often presenting with recurrent, spontaneous nosebleeds requiring medical attention rather than simple epistaxis clearing with direct pressure. The pathophysiology involves the nasal mucosa's rich vascular supply combined with high shear stress and minimal submucosal collagen, creating ideal conditions for bleeding when primary hemostasis is defective. Epistaxis may be spontaneous in severe disease or triggered by minor trauma, nasal infections, or dry winter air. Gingival bleeding occurs in approximately 40–50% of patients, presenting with spontaneous oozing of blood from the gingival margins, bleeding with minimal provocation during tooth brushing, or unexplained gingival erythema and inflammation. Excessive menstrual bleeding (menorrhagia) represents the most frequent bleeding manifestation in women with VWD, occurring in up to 75–90% of affected females, presenting with menses lasting >7 days, soaking through pads or tampons requiring frequent changes (every 1–2 hours), passage of clots >25 mm in diameter, or flooding episodes requiring urgent evaluation. The menorrhagia creates substantial morbidity including iron deficiency anemia, fatigue, dyspnea, and reduced quality of life. Women with menorrhagia and hemoglobin <10 g/dL without obvious structural pathology should be screened for VWD regardless of other bleeding symptoms.

Gastrointestinal bleeding occurs in 4–18% of patients with VWD, typically presenting as overt gross hematochezia (bright red blood per rectum) or melena (dark tarry stools), or occult bleeding detected through positive fecal occult blood testing causing iron deficiency anemia. The source varies but commonly involves angiodysplasia (arteriovenous malformations) in the colon or small intestine, occurring at higher prevalence in VWD patients compared to the general population; the mechanism involves defective primary hemostasis promoting bleeding from fragile, dilated vascular structures. GI bleeding may be mild and intermittent, presenting only as iron deficiency anemia, or can be severe and recurrent requiring transfusion and intervention. Some patients develop massive GI hemorrhage mimicking acute peptic ulcer disease or acute variceal bleeding, requiring urgent hospitalization and evaluation.

Patients with VWD experience prolonged bleeding following dental procedures, oral surgery, or minor trauma that normally causes minimal or brief bleeding in unaffected individuals. Excessive post-extraction bleeding after tooth removal, bleeding from small

Step 1 — quantify the bleeding phenotype: the ASH/ISTH/NHF/WFH 2021 diagnostic guideline recommends a validated bleeding assessment tool (ISTH-BAT) before laboratory testing; a normal score plus normal screening labs makes VWD very unlikely and spares further workup.

Heavy menstrual bleeding: hormonal therapy — combined estrogen-progestin contraceptives or the levonorgestrel-releasing IUD — or tranexamic acid; the ASH 2021 guideline and ACOG both endorse these over vWF concentrate for routine cycle control. Treat the resulting iron deficiency aggressively with oral or IV iron.

Surgery and delivery: raise vWF and FVIII activity with concentrate or DDAVP preoperatively and maintain through the healing period; obtain third-trimester levels, and continue coverage into the postpartum window when the pregnancy-induced rise in vWF abruptly falls.

Acquired VWD: treat the underlying driver — IVIG for paraprotein-associated disease, valve replacement for aortic stenosis.